Pharmaceuticals and Biotechnology

  • Jamie Rogers
Part of the Global Financial Markets book series (GFM)


The pharmaceutical (pharma) industry dominates the healthcare sector with a market capitalization of $2.7 trillion, while the biotechnology (biotech) industry is a significant component of the sector with a market capitalization of $863 billion. Both industries focus on the discovery, development, manufacturing and sale of prescription drugs, and have drivers that are both similar and unique to the industries. These include a focus on innovation and patents, drug licensing and a significant regulatory and political environment.


  1. US Congress, Office of Technology Assessment, Pharmaceutical R&D: Costs Risks and Rewards, OTA-M-522, Washington, DC: US Government Printing Office, February 1993.Google Scholar
  2. DiMasi, J and Grabowski, H. The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial And Decision Economics 28: 469–479, 2007.Google Scholar
  3. DiMasi, J, Hansen, R, and Grabowski, H. The price of innovation: new estimates of drug development costs, Journal of Health Economics, 22, 151–185, 2003.CrossRefGoogle Scholar
  4. DiMasi, J.A., Hansen, R.W., Grabowski, H.G., Lasagna, L., 1991. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10, 107–142.CrossRefGoogle Scholar
  5. Stewart, J. Allison, P. and Johnson, R. Putting a price on biotechnology, nature biotechnology, Volume 19 Sept 2001.CrossRefGoogle Scholar
  6. MIT Roundtable on Corporate Risk Management, Journal of Applied Corporate Finance, Volume 20 Number 4 Fall 2008.Google Scholar
  7. Myers, S. and Shyam-Sunder, L. Measuring pharmaceutical industry risk and the cost of capital, in Helms, R.B. (ed.) Competitive Strategies in the Pharmaceutical Industry, Washington, DC, American Enterprise Institute Press, 1996.Google Scholar
  8. Lütolf-Carroll, C, From Innovation to Cash Flows, Wiley, 2009.Google Scholar
  9. Kellogg, D. and Charnes, J.M. Real options valuation for a biotechnology company, Financial Analysts Journal, May/June 2000.CrossRefGoogle Scholar
  10. Kelly, M, Teufel, S, Fisher Investments on Health Care, Wiley, 2011.Google Scholar
  11. Myers, S. C., Howe, C. D., A Life Cycle Financial Model of Pharmaceutical R&D, Program On the Pharmaceutical Industry, MIT, 1997.Google Scholar
  12. Paul, S, Mytelka, D, Dunwiddie, C, Persinger, C, Munos, B, Lindborg, S and Schacht, A. How to improve R&D productivity: the pharmaceutical industry’s grand challenge, Nature Reviews Drug Discovery 9, 203–214, 2010.Google Scholar

Copyright information

© The Author(s) 2019

Authors and Affiliations

  • Jamie Rogers
    • 1
  1. 1.New YorkUSA

Personalised recommendations